Metastasis Research Laboratory, Grappe Disciplinaire de Génoprotéomique Appliquée (GIGA)–Cancer, Liège, Belgium.
Blood. 2011 Feb 24;117(8):2515-26. doi: 10.1182/blood-2010-08-298810. Epub 2010 Dec 29.
Dentin matrix protein 1 (DMP1) is a member of the small integrin-binding ligand N-linked glycoprotein (SIBLING) family, a group of proteins initially described as mineralized extracellular matrices components. More recently, SIBLINGs have been implicated in several key steps of cancer progression, including angiogenesis. Although proangiogenic activities have been demonstrated for 2 SIBLINGs, the role of DMP1 in angiogenesis has not yet been addressed. We demonstrate that this extracellular matrix protein induced the expression of vascular endothelial cadherin (VE-cadherin), a key regulator of intercellular junctions and contact inhibition of growth of endothelial cells that is also known to modulate vascular endothelial growth factor receptor 2 (VEGFR-2) activity, the major high-affinity receptor for VEGF. DMP1 induced VE-cadherin and p27(Kip1) expression followed by cell-cycle arrest in human umbilical vein endothelial cells (HUVECs) in a CD44-dependent manner. VEGF-induced proliferation, migration, and tubulogenesis responses were specifically blocked on DMP1 pretreatment of HUVECs. Indeed, after VE-cadherin induction, DMP1 inhibited VEGFR-2 phosphorylation and Src-mediated signaling. However, DMP1 did not interfere with basic fibroblast growth factor-induced angiogenesis. In vivo, DMP1 significantly reduced laser-induced choroidal neovascularization lesions and tumor-associated angiogenesis. These data enable us to put DMP1 on the angiogenic chessboard for the first time and to identify this protein as a new specific inhibitor of VEGF-induced angiogenesis.
牙本质基质蛋白 1(DMP1)是小整合素结合配体 N-连接糖蛋白(SIBLING)家族的成员,该家族最初被描述为矿化细胞外基质的组成部分。最近,SIBLING 被认为参与了癌症进展的几个关键步骤,包括血管生成。尽管已经证明了 2 种 SIBLING 具有促血管生成活性,但 DMP1 在血管生成中的作用尚未得到解决。我们证明这种细胞外基质蛋白诱导血管内皮钙黏蛋白(VE-cadherin)的表达,VE-cadherin 是细胞间连接和内皮细胞生长抑制的关键调节剂,也已知调节血管内皮生长因子受体 2(VEGFR-2)的活性,VEGFR-2 是 VEGF 的主要高亲和力受体。DMP1 以 CD44 依赖的方式诱导人脐静脉内皮细胞(HUVEC)中 VE-cadherin 和 p27(Kip1)的表达,随后导致细胞周期停滞。DMP1 预处理 HUVEC 可特异性阻断 VEGF 诱导的增殖、迁移和管腔形成反应。事实上,在 VE-cadherin 诱导后,DMP1 抑制 VEGFR-2 磷酸化和 Src 介导的信号转导。然而,DMP1 不干扰碱性成纤维细胞生长因子诱导的血管生成。在体内,DMP1 显著减少激光诱导的脉络膜新生血管病变和肿瘤相关的血管生成。这些数据使我们能够首次将 DMP1 置于血管生成棋盘上,并将该蛋白鉴定为一种新的 VEGF 诱导血管生成的特异性抑制剂。